Company: MIRM
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001759425-25-000032
Chunk: 353

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 1
Chunk 353
---
 into a Sales Agreement (the “2023 Sales Agreement”) with Leerink and Cantor Fitzgerald & Co. (the “Sales Agents”), pursuant to which the Company may, from time to time, sell up to an aggregate amount of $200.0 million of its common stock through the Sales Agents in an “at-the-market” offering (the “ATM Offering”). The Company is not required to sell shares under the 2023 Sales Agreement. Sales of the Company’s common stock, if any, under the 2023 Sales Agreement may be made in any transactions that are deemed to be “at the market offerings” as defined in Rule 415 under the Securities Act. The Company will pay a given designated Sales Agent a commission of up to 3.0% of the aggregate gross proceeds of any shares of common stock sold through such Sales Agent pursuant to the 2023 Sales Agreement. As of March 31, 2025, the Company had not issued any securities pursuant to the 2023 Sales Agreement.

17

Common Stock Reserved for IssuanceCommon stock reserved for issuance is as follows:  As of March 31,2025Stock options, restricted stock units and performance stock units issued and outstanding12,712,908Reserved for future stock awards or option grants2,577,799Reserved for employee stock purchase plan1,865,996Common stock issuable upon conversion of convertible notes9,964,058 27,120,761

11. Stock-Based Compensation

Stock OptionsThe following table summarizes stock option activity during the three months ended March 31, 2025 (in thousands, except share and per share data):  Number ofAwards Weighted-AverageExercisePriceWeighted-AverageRemainingContractualLife(in Years)AggregateIntrinsicValueOutstanding as of December 31, 2024 10,031,486$18.12 6.5$233,161 Granted1,416,911$47.76  Exercised(555,867)$11.44  Canceled and forfeited(55,494)$23.93  Outstanding as of March 31, 2025 10,837,036$22.31 6.8$250,484 Vested and exercisable as of March 31, 2025 6,772,788$15.46 5.5$200,429  The weighted-average grant date fair value per share of stock options granted during the three months